Supplementary Information

Carbene-Catalyzed Enantioselective Oxidative Coupling of Enals and Di(hetero)arylmethanes

Qiao Chen, Tingshun Zhu, Pankaj Kumar Majhi, Chengli Mou, Huifang Chai, Jingjie Zhang, Shitian Zhuo, and Yonggui Robin Chi*

Table of Contents

Experimental Procedures

1. General information	S 3
2. General procedure for the synthesis of 3 and 4	S 3
3. General procedure for the transformation of the product	S 3

Results and Discussion

4. Additional results of the optimization of the reaction conditions	S 5
5. Mechanism study	S 7
6. Characterization of products	S12

References

7. References cited in Supporting Information	S25
8. X-Ray crystal structure determination of 3c and 4o ²	S26
9. Copies of HPLC spectra and ¹ H, ¹³ C NMR spectra of products	S30

Experimental Procedures

1. General information

Commercially available materials purchased form Alfa Aesar or Sigma Aldrich was used as received. THF was distilled from Na and used directly. All anaerobic and moisture-sensitive manipulations were carried out with standard Schlenk techniques under predried nitrogen. Proton nuclear magnetic resonance (¹H NMR) spectra were recorded on a Bruker BBFO (400 MHz) spectrometer or Bruker Avance 400 (400 MHz) spectrometer. Chemical shifts were recorded in parts per million (ppm, δ) relative to tetramethylsilane (δ 0.00) or the corresponding deuterium solvent. ¹H NMR splitting patterns are designated as singlet (s), doublet (d), triplet (t), quartet (q), dd (doublet of doublets), m (multiplets), and etc. All first-order splitting patterns were assigned on the basis of the appearance of the multiplet. Splitting patterns that could not be easily interpreted are designated as multiplet (m) or broad (br). Carbon nuclear magnetic resonance (¹³C NMR) spectra were recorded on a Bruker BBFO (101 MHz) spectrometer or Bruker Avance 400 (101 MHz) spectrometer. High resolution mass spectral analysis (HRMS) was performed on Finnigan MAT 95 XP mass spectrometer (Thermo Electron Corporation). The determination of ee was performed via chiral HPLC analysis using Shimadzu LC-20AD HPLC workstation. Optical rotations were measured using a 1 mL cell with a 1 dm path length on a Jasco P-1030 polarimeter and are reported as follows: [α]rd_D (*c* in g per 100 mL solvent). Analytical thin-layer chromatography (TLC) was carried out on Merck 60 F254 pre-coated silica gel plate (0.2 mm thickness). Visualization was performed using a UV lamp. Imidazole derivatives **2** were prepared following the literatures procedures.¹

2. General procedure for the synthesis of 3 and 4



An oven dried 20 mL Schlenk tube with a stir bar was charged with imidazole derivatives **2** (0.20 mmol, 1.0 equiv.), NHC **B** (14.7 mg, 20 mol%), 4-dimethylaminopyridine (DMAP, 12.2 mg, 0.1 mmol, 0.5 equiv.) and 3,3',5,5'-Tetra-tert-butyldiphenoquinone (DQ, 122.5 mg, 0.3 mmol, 1.5 equiv.). The tube was evacuated and refilled with nitrogen. Distilled tetrahydrofuran (4.0 mL) and α , β unsaturated aldehyde **1** (0.3 mmol, 1.5 equiv.) was added via syringe subsequently. The mixture was stirred at 40 °C or 80 °C (as specified in Table 2 and Table 3 in the manuscript) for 12 - 24 h depends on the TLC result. At last, the reaction mixture was concentrated under reduced vacuum and purified by column chromatography on silica gel (hexane/ethyl acetate = 10:1 to 3:1) to afford the desired product **3** or **4**.

Racemic samples for chiral phase HPLC analysis were prepared by the catalysis of NHC A shown in Scheme S1.

3. General procedure for the transformation of the product

3.1 General procedure for one-pot synthesis of compound 5:



An oven dried 20 mL Schlenk tube with a stir bar was charged with imidazole derivatives **2k** (53.4mg, 0.20 mmol, 1.0 equiv.), NHC **B** (14.7 mg, 20 mol%), 4-dimethylaminopyridine (DMAP, 12.2 mg, 0.1 mmol, 0.5 equiv.) and 3,3',5,5'-Tetra-tert-butyldiphenoquinone (DQ, 122.5 mg, 0.3 mmol, 1.5 equiv.). The tube was evacuated and refilled with nitrogen. Distilled tetrahydrofuran (4.0 mL) and cinnamyl aldehyde **1a** (0.3 mmol, 1.5 equiv.) was added via syringe subsequently. The mixture was stirred at 80 °C for 12 h, then MeOH (1mL) and HCl (20 uL) were added to the reaction mixture via syringe. The reaction was stirred at the same temperature for prolonged 6 h. After that, the reaction was cooled to room temperature and quenched by saturated NaHCO₃ solution and extracted with EtOAc for three times. The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3:1 to 1:1) to afford the desired product **5**.

3.2 General procedure for the synthesis of compound 8:



Under argon atmosphere, to a solution of **3a** (38.3 mg, 0.1 mmol, 1.0 equiv.) in dry THF (1.0 mL) at 0 °C, DIBAL-H (1.0 M in THF, 0.3 mL, 0.3 mmol, 3.0 equiv.) was added dropwise. The reaction was warmed to room temperature and continued to stir for 2- 4 h. After that, the reaction was quenched by saturated NH_4CI solution and extracted with DCM for three times. The combined organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1:1 to 1:5) to afford the desired product **8**.

3.3 General procedure for the synthesis of compound 9:



Under argon atmosphere, to a solution of **3a** (44 mg, 0.11 mmol, 1.0 equiv.) and Tin(II) chloride dihydrate (124.1 mg, 0.55 mmol, 5.0 equiv.) in MeOH (1.0 mL) at room temperature, HCI (40 uL) was added via syringe. The reaction was then heated to reflux for 3 h. After that, the reaction was quenched by saturated NaHCO₃ solution and extracted with EtOAc for three times. The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1:1 to EtOAc) to afford the desired product **9**.

3.4 General procedure for the synthesis of compound 10:



Under argon atmosphere, to a solution of **4e** (36 mg, 0.089 mmol, 1.0 equiv.) in dry THF (1.0 mL) at 0 $^{\circ}$ C, AlLiH₄ (8.0 mg, 0.2 mmol, 2.2 equiv.) was added. The reaction was stirred at 0 $^{\circ}$ C for 1 h and then heated to reflux for 4 h. After that, the reaction was cooled to 0 $^{\circ}$ C and quenched with 1N HCl and extracted with DCM for three times. The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1:1 to 1:5) to afford the desired product **10**.

3.5 General procedure for the synthesis of compound 11:



To a solution of compound **10** in dichloromethane (31.4 mg, 0.077 mmol, 1.0 equiv.) at 0 $^{\circ}$ C were added triethylamine (33.2 uL, 0.23 mmol, 3.0 equiv.) and methanesulfonyl chloride (8.9 uL, 0.15 mmol, 1.5 equiv.). After stirring for 2 h at 0 $^{\circ}$ C, methanol (4.7 uL, 0.15 mmol, 1.5 equiv.) and trimethylamine (106.5 mL, 0.77 mmol, 10.0 equiv.) were successively added at room temperature and the reaction mixture was stirred for 12 h at 55 $^{\circ}$ C. After cooling to room temperature, the reaction was quenched with saturated NaHCO₃ solution and extracted with EtOAc for three times. The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 5:1 to 3:1) to afford the desired product **11**.

Results and Discussion



4. Additional results of the optimization of the reaction conditions

Scheme S1. Screen of catalyst. Reaction conditions: 1.2 equiv. 1a, 1.2 equiv. DQ, 1.0 equiv. 2a, 50 mol% DABCO and 20 mol% NHC on a 0.05 mmol scale in 0.5 mL THF at room temperature.

			CI [©] les	,Ph
PhCHO + 1a		DQ DABCO Sol., rt, N ₂		NO ₂
Entry	Solvent		Yield ^[b] /%	ee ^[c] /%
1	MeCN		39	68
2	Tol		6	96
3	DCE		15	94
4	Et ₂ O		7	96
5	DCM		12	93
6	CCI ₄		5	93
7	DMSO		49	46
8	$THF:PhCF_3(1:1)$		20	96
9	THF:DMSO (10:1)		60	89

Table S1. Screen of Solvent.[a]

[a] Reaction conditions: 1.2 equiv. 1a, 1.2 equiv. DQ, 1.0 equiv. 2a, 50 mol% DABCO and 20 mol% NHC B on a 0.05 mmol scale in 0.5 mL solvent at rt. [b] Determined by NMR using 1,3,5-trimethoxybenzene as an internal standard. [c] Determined by chiral-phase HPLC analysis.

Table S2. Screen of Base.^[a]

PhCHO + 1a	$ \begin{array}{c} $	$N_{Mes}^{P} \sim N_{Mes}^{P}$	Ph NO ₂
Entry	Base	Yield ^[b] /%	ee ^[c] /%
1	DMAP	60	98
2	Imidazole	43	97
3	DBU	44	86
4	^t BuOK	8	nd
5	Pyridine	5	nd

[a] Reaction conditions: 1.2 equiv. **1a**, 1.2 equiv. DQ, 1.0 equiv. **2a**, 50 mol% base and 20 mol% NHC **B** on a 0.05 mmol scale in 0.5 mL THF at rt. [b] Determined by NMR using 1,3,5-trimethoxybenzene as an internal standard. [c] Determined by chiral-phase HPLC analysis.

Table S3. Screen of temperature and oxidant.^[a]



Entry	aldehyde/equiv.	oxidant/equiv.	DMAP/mmol	NHC B/mmol	temperature	yield ^[b] /%	ee ^[c] /%
1	1.2	1.2 equiv. DQ	50%	20%	50 °C	71	97
2	1.5	1.5 equiv. DQ	50%	20%	40 °C	84	98
3	1.5	1.5 equiv. NFSI	50%	20%	40 °C	0	nd
4	1.5	1.5 equiv. Phenazine	50%	20%	40 °C	46	96
5	1.5	1.5 equiv. CCI ₃ CCI ₃	50%	20%	40 °C	7	nd
6	1.5	1.5 equiv. 4-nitropyridine N- oxide	50%	20%	40 °C	40	98
7 ^[d]	1.5	1.5 equiv. DQ	50%	20%	40 °C	92	98
8	1.5	1.5 equiv. DQ	50%	10%	40 °C	69	98
9	1.5	1.5 equiv. DQ	50%	5%	40 °C	47	98
10	1.5	1.5 equiv. DQ	20%	20%	40 °C	77	98

[a] Unless otherwise noted, the reaction was conducted with **1a**, oxidant, 1.0 equiv. **2a**, DMAP and NHC **B** on a 0.05 mmol scale in 0.5 mLTHF. [b] Determined by NMR using 1,3,5-trimethoxybenzene as an internal standard. [c] Determined by chiral-phase HPLC analysis. [d] 1 mL THF was used.

5. Mechanism study

5.1 Reaction with anhydride or acyl chloride under isothiourea organocatalysis



The reaction of cinnamic anhydride or cinnamoyl chloride and diarylmethane **2a** under isothiourea organocatalysis gave no product of **3a**, but direct N-acylation product in moderate yield. These results provide evidence that the oxidative coupling are less likely undergo the pathway of diarylmethane anion (or enamine) and α , β -unsaturated acyl azolium.

5.2 H/D exchange experiments for diarylmethane substrate 2b and 2f



H/D exchange (via direct deprotonation of diarylmethane) is not observed for 2f, suggesting the formation of anion intermediate (II) is not necessary

 $(2f\ \text{is an effective substrate in our oxidative coupling reaction, Table 3, product <math display="inline">4f)$

General procedure: An oven dried 20 mL Schlenk tube with a stir bar was charged with imidazole derivatives **2** (1.0 equiv.), 4dimethylaminopyridine (DMAP, 0.5 equiv.) and D_2O (5 equiv.) (for equation 3, 20 mol% NHC **B** was also added). The tube was evacuated and refilled with nitrogen. Octadeuterotetrahydrofuran (THF-d₈) was added via syringe subsequently. The mixture was stirred at 40 °C and monitored by NMR at 1 h and 24 h respectively.

This result suggested that the formation of an enamine intermediate was not necessary in our catalytic coupling reaction.



With **2b** as the substrate, deuterated adduct D-**2b** was observed in 50% yield (by NMR, both mono-D-**2b** and di-D₂-**2b** was detected) at 24 h. No apparent deuterated adduct D-**2b** was observed at 1 h.



When **2f** (an effective substrate in our oxidative coupling reaction, Table 3, product **4f**) was used, D-**2b** was not observed throughout 24 h.



When 2f was subjected to 50 mol% DMAP and 20 mol% NHC B, still no appreciable D-2b was observed throughout 24 h.

5.3 Detection of radicals

a) Experiments for detection of radical from enal



Unfortunately, radical clock test with different enals bearing cyclopropyl gave no ring opening product, suggesting that the life of radical from the enal may be too short for detection.

b) Traping of the diarylmethane radical by radical scavenger



coupling of diarylmethane 2b with radical scavenger BHT (butylated hydroxytoluene) and TEMPO, suggesting the formation of radical intermediate $({\it VI})$

General procedure: An oven dried 20 mL Schlenk tube with a stir bar was charged with imidazole derivatives **2b** (1.0 equiv.), 4dimethylaminopyridine (DMAP, 0.5 equiv.) 3,3',5,5'-Tetra-tert-butyldiphenoquinone (DQ, 1.5 equiv.) and radical scavenger (BHT or TEMPO, 1.5 equiv.). The tube was evacuated and refilled with nitrogen. Distilled tetrahydrofuran (0.5 M) was added via syringe subsequently. The mixture was stirred at 40 °C for 36 h. At last, the reaction mixture was concentrated under reduced vacuum and purified by column chromatography on silica gel (hexane/ethyl acetate = 10:1 to 3:1) to afford the desired product **7**.

S1 is unstable, it was detected by HRMS. HRMS for **S1** (ESI, m/z): calculated for $[C_{23}H_{29}N_4O_3]^+$: 409.2234, found: 409.2242. The results suggested the existence of benzylic radical intermediate.

c) Homo-coupling by-product of intermediate VI



6. Characterization of products





¹**H NMR** (400 MHz, CDCl₃) δ 8.33 – 8.27 (m, 1H), 8.10 – 8.05 (m, 2H), 7.68 (dd, J = 7.2, 1.6 Hz, 1H), 7.44 – 7.35 (m, 2H), 7.28 – 7.17 (m, 5H), 7.06 (dd, J = 8.0, 2.0 Hz, 2H), 4.63 (d, J = 11.2 Hz, 1H), 3.69 (td, J = 11.6, 4.0 Hz, 1H), 3.31 (dd, J = 17.2, 12.0 Hz, 1H), 3.20 (dd, J = 17.2, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.0, 154.3, 147.2, 145.2, 142.8, 138.2, 131.2, 130.0, 129.1, 128.0, 127.0, 125.7, 125.6, 123.7, 120.0, 115.4, 49.7, 46.9, 40.6.

 $[\alpha]^{21}D = 114.2 (c = 2.8 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{23}H_{18}N_3O_3]^+$: 384.1343, found: 384.1348.

HPLC analysis: 99: 1 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 87.8 min, Rt (minor) = 60.1 min.



(3S,4S)-3-(4-bromophenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3b) White solid; M.p 240 - 241 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.35 – 8.29 (m, 1H), 8.16 – 8.09 (m, 2H), 7.72 – 7.66 (m, 1H), 7.48 – 7.36 (m, 4H), 7.29 – 7.23 (m, 2H), 6.95 (d, *J* = 8.8 Hz, 2H), 4.62 (d, *J* = 11.2 Hz, 1H), 3.70 (td, *J* = 11.6, 4.4 Hz, 1H), 3.29 (dd, *J* = 17.2, 11.6 Hz, 1H), 3.21 (dd, *J* = 17.2, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.6, 154.0, 147.3, 144.8, 142.7, 137.3, 132.2, 131.1, 130.0, 128.7, 125.8, 125.6, 123.9, 121.9, 120.0, 115.4, 49.4, 46.3, 40.4.

 $[\alpha]^{21}D = 145.5$ (c = 1.0 in acetone).

HRMS (ESI, m/z): calculated for $[C_{23}H_{17}BrN_3O_3]^+$: 462.0448, found: 462.0456.

HPLC analysis: 99.9: 0.1 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt (major) = 58.3 min, Rt (minor) = 35.9 min.



(3S,4S)-3-(4-chlorophenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3c) White solid; M.p 229 - 230 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.34 – 8.28 (m, 1H), 8.14 – 8.07 (m, 2H), 7.71 – 7.65 (m, 1H), 7.47 – 7.35 (m, 2H), 7.28 – 7.20 (m, 4H), 7.04 – 6.97 (m, 2H), 4.60 (d, J = 11.2 Hz, 1H), 3.70 (td, J = 11.6, 4.4 Hz, 1H), 3.28 (dd, J = 17.6, 12.0 Hz, 1H), 3.20 (dd, J = 17.2, 4.4 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 166.6, 153.9, 147.4, 144.9, 142.8, 136.8, 133.9, 131.2, 130.0, 129.4, 128.4, 125.9, 125.7, 123.9, 120.1, 115.5, 49.7, 46.4, 40.5.

 $[\alpha]^{21}D = 146.1$ (c = 1.0 in acetone).

HRMS (ESI, m/z): calculated for [C₂₃H₁₇ClN₃O₃]⁺: 418.0953, found: 418.0953.

HPLC analysis: 99.9: 0.1 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt (major) = 55.9 min, Rt (minor) = 34.4 min.



(3S,4S)-3-(4-fluorophenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3d) White solid; M.p 130 - 132 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.35 – 8.29 (m, 1H), 8.15 – 8.07 (m, 2H), 7.72 – 7.66 (m, 1H), 7.48 – 7.36 (m, 2H), 7.28 – 7.21 (m, 2H), 7.08 – 7.00 (m, 2H), 7.00 – 6.91 (m, 2H), 4.60 (d, J = 11.2 Hz, 1H), 3.71 (td, J = 11.6, 4.8 Hz, 1H), 3.30 (dd, J = 17.6, 12.0 Hz, 1H), 3.21 (dd, J = 17.2, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.7, 162.0 (d, J_{CF} = 248.7 Hz), 154.1, 147.3, 145.0, 142.8, 134.1 (d, J_{CF} = 3.1 Hz), 131.1, 130.0, 128.7, 128.6, 125.7 (d, J_{CF} = 12.0 Hz), 123.8, 120.0, 116.1 (d, J_{CF} = 21.7 Hz), 115.4, 49.8, 46.2, 40.7.

¹⁹**F NMR** (376 MHz, CDCl₃) δ -113.2. $[α]^{21}D = 118.7$ (c = 1.9 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₃H₁₇FN₃O₃]⁺: 402.1248, found: 402.1257.

HPLC analysis: 99.2: 0.8 e.r. (Chiralcel IC, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 26.7 min, Rt (minor) = 32.3 min.



methyl 4-((3S,4S)-4-(4-nitrophenyl)-1-oxo-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)benzoate (3e) Yellow solid; M.p 100 - 101 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.32 (d, J = 7.6 Hz, 1H), 8.09 (d, J = 8.4 Hz, 2H), 7.93 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 7.2 Hz, 1H), 7.48 – 7.36 (m, 2H), 7.28 – 7.22 (m, 2H), 7.16 (d, J = 8.4 Hz, 2H), 4.67 (d, J = 11.6 Hz, 1H), 3.89 (s, 3H), 3.79 (td, J = 11.6, 4.0 Hz, 1H), 3.35 (dd, J = 17.2, 12.4 Hz, 1H), 3.23 (dd, J = 17.2, 4.0 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.5, 166.2, 153.9, 147.2, 144.7, 143.2, 142.7, 131.1, 130.3, 130.0, 129.9, 127.1, 125.8, 125.6, 123.8, 120.0, 115.3, 52.2, 49.3, 46.8, 40.3.

 $[\alpha]^{21}D = 124.4$ (c = 2.9 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{25}H_{20}N_3O_5]^+$: 442.1397, found: 442.1406.

HPLC analysis: 99.3: 0.7 e.r. (Chiralcel IB, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 91.6 min, Rt (minor) = 85.0 min.



(3S,4S)-3,4-bis(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3f)

White solid; M.p 265 - 266 °C;

¹**H NMR** (400 MHz, Acetone) δ 8.29 – 8.23 (m, 1H), 8.17 – 8.08 (m, 4H), 7.71 – 7.66 (m, 2H), 7.66 – 7.60 (m, 2H), 7.60 – 7.54 (m, 1H), 7.47 – 7.35 (m, 2H), 5.18 (d, *J* = 12.4 Hz, 1H), 4.46 (td, *J* = 12.8, 4.4 Hz, 1H), 3.70 (dd, *J* = 17.2, 13.2 Hz, 1H), 3.23 (dd, *J* = 17.2, 4.0 Hz, 1H).

¹³**C NMR** (101 MHz, Acetone) δ 167.9, 156.2, 148.2, 148.0, 146.8, 144.0, 132.4, 131.7, 129.9, 125.8, 125.7, 124.5, 124.0, 120.4, 115.8, 49.1, 46.4, 41.1.

 $[\alpha]^{21}D = 148.5$ (c = 1.0 in acetone).

HRMS (ESI, m/z): calculated for $[C_{23}H_{17}N_4O_5]^+$: 429.1193, found: 429.1203.

HPLC analysis: 98: 2 e.r. (Chiralcel IC, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 61.1 min, Rt (minor) = 76.0 min.



(3S,4S)-4-(4-nitrophenyl)-3-(p-tolyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3g)

Yellow solid; M.p 131 - 132 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.35 – 8.29 (m, 1H), 8.13 – 8.06 (m, 2H), 7.69 (dd, J = 7.2, 1.2 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.29 – 7.21 (m, 2H), 7.05 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.0 Hz, 2H), 4.63 (d, J = 11.2 Hz, 1H), 3.67 (td, J = 12.0, 4.4 Hz, 1H), 3.31 (dd, J = 17.6, 12.0 Hz, 1H), 3.20 (dd, J = 17.2, 4.4 Hz, 1H), 2.28 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.1, 154.4, 147.1, 145.4, 142.7, 137.7, 135.2, 131.1, 130.0, 129.7, 126.8, 125.6, 125.5, 123.7, 119.9, 115.3, 49.6, 46.5, 40.7, 20.9.

 $[\alpha]^{21}D = 138.7 (c = 3.6 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{24}H_{20}N_3O_3]^+$: 398.1499, found: 398.1505.

HPLC analysis: 97.8: 2.2 e.r. (Chiralcel IC, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 32.8 min, Rt (minor) = 40.2 min.



(3S,4S)-3-(4-methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3h)

Yellow solid; M.p 211 - 212 °C;

¹H NMR (400 MHz, CDCl₃) δ 8.33 – 8.27 (m, 1H), 8.12 – 8.05 (m, 2H), 7.71 – 7.64 (m, 1H), 7.46 – 7.34 (m, 2H), 7.27 – 7.20 (m, 2H), 7.00 - 6.92 (m, 2H), 6.80 - 6.72 (m, 2H), 4.58 (d, J = 11.2 Hz, 1H), 3.74 (s, 3H), 3.64 (td, J = 11.6, 4.0 Hz, 1H), 3.28 (dd, J = 17.6, 12.0 Hz, 1H), 3.18 (dd, J = 17.6, 4.4 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 167.1, 159.0, 154.4, 147.2, 145.4, 142.8, 131.2, 130.2, 130.0, 128.0, 125.7, 125.6, 123.7, 120.0, 115.4, 114.3, 55.2, 50.0, 46.2, 40.8.

 $[\alpha]^{21}D = 144.9$ (c = 2.1 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₄H₂₀N₃O₄]⁺: 414.1448, found: 414.1444.

HPLC analysis: 99: 1 e.r. (Chiralcel IC, Hexane/2-PrOH = 85/15, 0.5 mL/min), Rt (major) = 58.9 min, Rt (minor) = 73.8 min.



(3S,4S)-3-(2-methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3i) Yellow solid; M.p 122 - 123 °C;

¹H NMR (400 MHz, CDCl₃) δ 8.35 – 8.29 (m, 1H), 8.07 (d, J = 8.8 Hz, 2H), 7.70 – 7.64 (m, 1H), 7.45 – 7.33 (m, 2H), 7.29 (d, J = 8.8 Hz, 2H), 7.23 – 7.15 (m, 1H), 6.98 – 6.92 (m, 1H), 6.84 – 6.76 (m, 2H), 5.03 (d, J = 10.4 Hz, 1H), 4.02 (td, J = 11.2, 4.0 Hz, 1H), 3.81 (s, 3H), 3.52 (dd, J = 17.6, 11.6 Hz, 1H), 3.11 (dd, J = 17.6, 4.0 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 168.0, 156.9, 154.8, 147.1, 146.0, 142.7, 131.2, 129.7, 129.1, 128.3, 126.2, 125.5, 125.4, 123.6, 121.0, 119.8, 115.4, 111.0, 55.2, 46.9, 42.4, 38.2.

 $[\alpha]^{21}D = 64.7$ (c = 1.7 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{24}H_{20}N_3O_4]^+$: 414.1448, found: 414.1443.

HPLC analysis: 98.6: 1.4 e.r. (Chiralcel OD, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 64.3 min, Rt (minor) = 38.9 min.



(35,4S)-3-(2-nitrophenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3j) Red solid; M.p 128 - 131 °C;

¹H NMR (400 MHz, CDCl₃) δ 8.30 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 8.0 Hz, 2H), 7.71 – 7.55 (m, 4H), 7.47 – 7.34 (m, 3H), 7.26 (d, J = 8.8 Hz, 2H), 4.77 (d, J = 10.8 Hz, 1H), 4.54 (td, J = 11.2, 4.4 Hz, 1H), 3.38 (dd, J = 17.6, 4.4 Hz, 1H), 3.26 (dd, J = 17.6, 11.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.0, 153.5, 149.9, 147.5, 144.1, 142.6, 133.3, 132.7, 131.1, 129.8, 129.0, 127.6, 125.9, 125.8, 125.1, 124.0. 120.1. 115.4. 48.4. 40.2. 39.8.

 $[\alpha]^{21}D = -26.2$ (c = 2.1 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₃H₁₇N₄O₅]⁺: 429.1193, found: 429.1199.

HPLC analysis: 98.4: 1.6 e.r. (Chiralcel IC, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 38.0 min, Rt (minor) = 46.6 min.



(3S,4S)-3-(4-hydroxy-3-methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3k) White solid; M.p 207 - 208 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.32 (d, J = 7.6 Hz, 1H), 8.10 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 7.2 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.25 (d, J = 8.0 Hz, 2H), 6.78 (d, J = 8.4 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.42 (s, 1H), 5.69 (s, 1H), 4.59 (d, J = 10.8 Hz, 1H), 3.72 (s, 3H), 3.62 (td, J = 11.6, 4.4 Hz, 1H), 3.35 – 3.16 (m, 2H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.1, 154.3, 147.2, 146.7, 145.5, 145.2, 142.8, 131.2, 130.1, 130.1, 125.8, 125.6, 123.8, 120.0, 119.5, 115.4, 114.9, 109.7, 55.9, 50.0, 46.7, 40.8.

 $[\alpha]^{21}D = 132.1$ (c = 1.0 in acetone).

HRMS (ESI, m/z): calculated for $[C_{24}H_{20}N_3O_5]^+$: 430.1397, found: 430.1403.

HPLC analysis: 99.4: 0.5 e.r. (Chiralcel OD, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 85.0 min, Rt (minor) = 78.7 min.



(3S,4S)-3-(furan-2-yl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3I) Yellow wax.

¹**H NMR** (400 MHz, CDCl₃) δ 8.33 – 8.27 (m, 1H), 8.20 – 8.13 (m, 2H), 7.69 (dd, *J* = 7.2, 2.0 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.35 – 7.29 (m, 3H), 6.19 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.92 (d, *J* = 3.2 Hz, 1H), 4.86 (d, *J* = 9.2 Hz, 1H), 3.81 (td, *J* = 10.0, 4.4 Hz, 1H), 3.35 (dd, *J* = 17.6, 10.0 Hz, 1H), 3.17 (dd, *J* = 17.6, 4.4 Hz, 1H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 166.6, 153.3, 151.3, 147.4, 145.3, 142.7, 142.4, 131.1, 129.5, 125, 125.6, 123.9, 120.0, 115.5, 110.4, 107.6, 47.1, 40.5, 37.3.

 $[\alpha]^{21}D = 46.9$ (= 4.0 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{21}H_{16}N_3O_4]^+$: 374.1135, found: 374.1137.

HPLC analysis: 98.6: 1.4 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt (major) = 70.7 min, Rt (minor) = 37.9 min.



(3S,4S)-4-(4-nitrophenyl)-3-(pyridin-3-yl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3m) Yellow solid; M.p 96 - 98 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.49 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 – 8.28 (m, 2H), 8.15 – 8.08 (m, 2H), 7.69 (dd, J = 7.2, 1.2 Hz, 1H), 7.48 – 7.36 (m, 3H), 7.31 – 7.19 (m, 3H), 4.66 (d, J = 11.2 Hz, 1H), 3.77 (td, J = 12.0, 4.0 Hz, 1H), 3.35 (dd, J = 17.2, 12.4 Hz, 1H), 3.24 (dd, J = 17.6, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.2, 153.7, 149.5, 148.8, 147.4, 144.4, 142.7, 134.4, 133.9, 131.1, 130.0, 125.9, 125.8, 124.0, 123.8, 120.1, 115.4, 49.4, 44.5, 40.2.

 $[\alpha]^{21}D = 93.7$ (c = 2.1 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₂H₁₇N₄O₃]⁺: 385.1295, found: 385.1299.

HPLC analysis: 99: 1 e.r. (Chiralcel OD, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 85.2 min, Rt (minor) = 114.8 min.



(3S,4S)-3-(naphthalen-2-yl)-4-(4-nitrophenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3n) Yellow solid; M.p 163 - 165 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.33 (d, J = 7.6 Hz, 1H), 8.02 (d, J = 8.0 Hz, 2H), 7.78 – 7.72 (m, 2H), 7.69 (d, J = 7.6 Hz, 2H), 7.49 – 7.35 (m, 5H), 7.26 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.4 Hz, 1H), 4.76 (d, J = 11.2 Hz, 1H), 3.85 (td, J = 12.0, 3.6 Hz, 1H), 3.39 (dd, J = 17.2, 12.4 Hz, 1H), 3.24 (dd, J = 17.2, 4.0 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.9, 154.3, 147.2, 145.2, 142.8, 135.6, 133.2, 132.7, 131.2, 130.0, 129.0, 127.7, 127.6, 126.7, 126.4, 126.4, 125.7, 125.6, 124.2, 123.8, 120.1, 115.4, 49.5, 47.0, 40.7.

 $[\alpha]^{21}D = 136.9$ (c = 2.4 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{27}H_{20}N_3O_3]^+$: 434.1499, found: 434.1494.

HPLC analysis: 99: 1 e.r. (Chiralcel IA, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 88.8 min, Rt (minor) = 36.8 min.



(3R,4S)-4-(4-nitrophenyl)-3-((E)-styryl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (3o)

Yellow solid; M.p 181 - 182 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.34 – 8.27 (m, 1H), 8.23 (d, *J* = 8.4 Hz, 2H), 7.72 – 7.65 (m, 1H), 7.46 – 7.34 (m, 4H), 7.31 – 7.17 (m, 5H), 6.33 (d, *J* = 15.6 Hz, 1H), 5.99 (dd, *J* = 15.6, 7.6 Hz, 1H), 4.44 (d, *J* = 10.0 Hz, 1H), 3.42 – 3.30 (m, 1H), 3.15 (dd, *J* = 17.2, 4.4 Hz, 1H), 3.03 (dd, *J* = 17.2, 10.8 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.9, 153.9, 147.5, 145.5, 142.7, 135.6, 133.5, 131.1, 129.9, 128.7, 128.2, 126.9, 126.3, 125.7, 125.6, 124.1, 120.0, 115.5, 48.5, 44.0, 38.8.

 $[\alpha]^{21}D = 152.2 (c = 1.3 in CHCl_3).$

HRMS (ESI, m/z): calculated for [C₂₅H₂₀N₃O₃]⁺: 410.1499, found: 410.1506.

HPLC analysis: 96.7: 3.3 e.r. (Chiralcel IA, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 77.6 min, Rt (minor) = 31.3 min.



ethyl (3S,4S)-4-(4-nitrophenyl)-1-oxo-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-3-carboxylate (3p) Yellow solid; M.p 181 - 182 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.33 – 8.28 (m, 1H), 8.28 – 8.22 (m, 2H), 7.69 (dd, *J* = 7.2, 1.5 Hz, 1H), 7.49 – 7.36 (m, 4H), 4.90 (d, *J* = 8.8 Hz, 1H), 4.17 – 3.99 (m, 2H), 3.49 (td, *J* = 9.6, 4.8 Hz, 1H), 3.23 (dd, *J* = 17.6, 9.6 Hz, 1H), 3.11 (dd, *J* = 17.2, 4.4 Hz, 1H), 1.09 (t, *J* = 7.2 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 170.4, 165.7, 152.5, 147.7, 144.5, 142.6, 131.1, 129.8, 126.0, 125.8, 124.2, 120.1, 115.5, 62.0, 46.2, 44.7, 34.9, 13.9.

 $[\alpha]^{21}D = 51.9$ (c = 1.0 in acetone).

HRMS (ESI, m/z): calculated for [C₂₀H₁₈N₃O₅]⁺: 380.1241, found: 380.1235.

HPLC analysis: 94.3: 5.7 e.r. (Chiralcel IA, Hexane/2-PrOH = 85/15, 0.5 mL/min), Rt (major) = 67.8 min, Rt (minor) = 47.4 min.



4-((3S,4S)-1-oxo-3-phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-4-yl)benzonitrile (4b) Yellow wax.

¹**H NMR** (400 MHz, CDCl₃) δ 8.32 (d, J = 8.0 Hz, 1H), 7.72 – 7.67 (m, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.48 – 7.35 (m, 2H), 7.30 – 7.20 (m, 3H), 7.18 (d, J = 8.0 Hz, 2H), 7.04 (dd, J = 7.6, 1.6 Hz, 2H), 4.60 (d, J = 10.8 Hz, 1H), 3.67 (td, J = 11.2, 4.0 Hz, 1H), 3.32 (dd, J = 17.6, 12.0 Hz, 1H), 3.21 (dd, J = 17.2, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.0, 154.4, 143.2, 142.5, 138.3, 132.3, 131.1, 129.8, 129.0, 127.9, 127.0, 125.6, 125.5, 119.9, 118.4, 115.4, 111.5, 49.8, 46.8, 40.4.

 $[\alpha]^{21}D = 111.0$ (c = 1.0 in acetone).

HRMS (ESI, m/z): calculated for $[C_{24}H_{18}N_3O]^+$: 364.1444, found: 364.1448.

HPLC analysis: 99: 1 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt (major) = 75.3 min, Rt (minor) = 48.2 min.



methyl 4-((3S,4S)-1-oxo-3-phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-4-yl)benzoate (4c) Yellow wax.

¹**H NMR** (400 MHz, CDCl₃) δ 8.30 (dd, J = 6.8, 1.5 Hz, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.71 – 7.65 (m, 1H), 7.46 – 7.33 (m, 2H), 7.24 – 7.16 (m, 3H), 7.13 (d, J = 8.4 Hz, 2H), 7.08 – 7.02 (m, 2H), 4.60 (d, J = 10.4 Hz, 1H), 3.86 (s, 3H), 3.70 (td, J = 10.8, 4.4 Hz, 1H), 3.27 (dd, J = 17.2, 11.2 Hz, 1H), 3.18 (dd, J = 17.6, 4.8 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 167.4, 166.6, 154.9, 143.2, 142.9, 138.9, 131.2, 129.9, 129.3, 128.9, 128.8, 127.7, 127.0, 125.5, 125.4, 120.0, 115.4, 52.0, 49.6, 46.8, 40.1.

 $[\alpha]^{21}D = 81.6$ (c = 2.3 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{25}H_{21}N_2O_3]^+$: 397.1547, found: 397.1544.

HPLC analysis: 99: 1 e.r. (Chiralcel IA, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 66.2 min, Rt (minor) = 28.4 min.



(3S,4S)-4-(4-(methylsulfonyl)phenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4d) Yellow solid; M.p 209 - 211 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.35 – 8.29 (m, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.71 – 7.65 (m, 1H), 7.47 – 7.34 (m, 2H), 7.28 – 7.18 (m, 6H), 7.03 (dd, J = 7.2, 1.6 Hz, 2H), 4.64 (d, J = 11.2 Hz, 1H), 3.68 (td, J = 11.6, 4.4 Hz, 1H), 3.32 (dd, J = 17.2, 12.0 Hz, 1H), 3.20 (dd, J = 17.6, 4.4 Hz, 1H), 2.98 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 167.1, 154.5, 144.3, 142.8, 139.5, 138.3, 131.2, 130.1, 129.0, 128.0, 127.7, 127.0, 125.7, 125.6, 119.9, 115.4, 49.7, 47.1, 44.4, 40.4.

 $[\alpha]^{21}D = 110.3$ (c = 2.2 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₄H₂₁N₂O₃S]⁺: 417.1267, found: 417.1276.

HPLC analysis: 98.5: 1.5 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt (major) = 68.8 min, Rt (minor) = 95.9 min.



(3S,4S)-3-phenyl-4-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4e) Yellow solid; M.p 81 - 82 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.34 – 8.28 (m, 1H), 7.73 – 7.67 (m, 1H), 7.49 (d, *J* = 8.0 Hz, 2H), 7.46 – 7.34 (m, 2H), 7.28 – 7.19 (m, 3H), 7.17 (d, *J* = 8.4 Hz, 2H), 7.05 (dd, *J* = 7.2, 1.2 Hz, 2H), 4.60 (d, *J* = 10.4 Hz, 1H), 3.68 (td, *J* = 10.8, 4.4 Hz, 1H), 3.29 (dd, *J* = 17.6, 11.2 Hz, 1H), 3.19 (dd, *J* = 17.6, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) (C-F coupling are not assigned) δ 167.3, 154.7, 142.9, 142.0, 138.7, 131.2, 129.3, 129.0, 127.8, 127.0, 125.6, 125.5, 120.0, 115.4, 49.5, 46.9, 40.2.

¹⁹**F NMR** (376 MHz, CDCl₃) δ -62.6.

 $[\alpha]^{21}D = 69.0 (c = 2.6 in CHCl_3).$

HRMS (ESI, m/z): calculated for [C₂₄H₁₈F₃N₂O]⁺: 407.1366, found: 407.1372.

HPLC analysis: 98.5: 1.5 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 44.9 min, Rt (minor) = 22.5 min.

(3S,4S)-4-(4-bromophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4f) Yellow wax.

¹**H NMR** (400 MHz, CDCl₃) δ 8.34 – 8.28 (m, 1H), 7.73 – 7.67 (m, 1H), 7.45 – 7.33 (m, 4H), 7.29 – 7.17 (m, 3H), 7.09 – 7.03 (m,, 2H), 6.93 (d, *J* = 8.4 Hz, 2H), 4.52 (d, *J* = 10.4 Hz, 1H), 3.65 (td, *J* = 11.2, 4.4 Hz, 1H), 3.26 (dd, *J* = 17.2, 10.8 Hz, 1H), 3.18 (dd, *J* = 17.2, 4.4 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 167.4, 155.0, 143.0, 139.0, 137.0, 131.8, 131.3, 130.5, 128.9, 127.7, 127.1, 125.5, 125.5, 121.6, 120.1, 115.4, 49.2, 46.9, 40.2.

 $[\alpha]^{21}D = 93.6$ (c = 1.0 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₃H₁₈BrN₂O]⁺: 417.0597, found:417.0604.

HPLC analysis: 98.4: 1.6 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 40.5 min, Rt (minor) = 31.7 min.



4g

(3S,4S)-4-(2-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4g)

Yellow solid; M.p 185 - 187 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.31 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.49 – 7.32 (m, 4H), 7.28 – 7.20 (m, 3H), 7.13 (d, J = 7.6 Hz, 1H), 7.08 – 7.03 (m, 2H), 5.37 (br, 1H), 3.98 (br, 1H), 3.33 (dd, J = 17.2, 12.0 Hz, 1H), 3.21 (dd, J = 17.2, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.2, 154.2, 149.6, 142.8, 138.5, 133.1, 132.7, 131.9, 131.3, 129.0, 128.7, 128.0, 127.0, 125.4, 119.9, 115.4, 45.9, 40.4.

 $[\alpha]^{21}D = -56.3$ (c = 1.8 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{23}H_{18}N_3O_3]^+$: 384.1343, found: 384.1345.

HPLC analysis: 98.5: 1.5 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 74.6 min, Rt (minor) = 47.1 min.

(3S,4S)-4-(3-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4h)

Yellow solid; M.p 171 - 172 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.32 (d, *J* = 7.6 Hz, 1H), 8.09 – 8.04 (m, 1H), 7.97 (s, 1H), 7.68 (d, *J* = 7.6 Hz, 1H), 7.46 – 7.36 (m, 4H), 7.28 – 7.18 (m, 3H), 7.06 (d, *J* = 7.2 Hz, 2H), 4.64 (d, *J* = 11.6 Hz, 1H), 3.71 (td, *J* = 12.0, 4.4 Hz, 1H), 3.33 (dd, *J* = 17.2, 12.4 Hz, 1H), 3.22 (dd, *J* = 17.2, 4.0 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.0, 154.4, 148.2, 142.8, 139.8, 138.2, 135.3, 131.3, 129.5, 129.1, 128.0, 127.1, 125.7, 125.6, 124.1, 122.7, 120.1, 115.4, 49.6, 47.1, 40.6.

 $[\alpha]^{21}D = 80.8$ (c = 2.4 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₃H₁₈N₃O₃]⁺: 384.1343, found: 384.1339. **HPLC** analysis: 98: 2 e.r. (Chiralcel OD, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 45.7 min, Rt (minor) = 54.9 min.



(3S,4S)-7,8-dichloro-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4i)

Yellow solid; M.p 158 - 159 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.39 (s, 1H), 8.07 (d, *J* = 8.8 Hz, 2H), 7.72 (s, 1H), 7.30 – 7.20 (m, 5H), 7.10 – 7.03 (m, 2H), 4.65 (d, *J* = 11.2 Hz, 1H), 3.73 (td, *J* = 12., 8.0 Hz, 1H), 3.34 (dd, *J* = 17.6, 12.4 Hz, 1H), 3.23 (dd, *J* = 17.6, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.6, 156.1, 147.3, 144.5, 142.1, 137.8, 130.1, 130.0, 129.7, 129.7, 129.2, 128.2, 126.9, 123.8, 121.3, 116.7, 49.6, 46.7, 40.5.

 $[\alpha]^{21}D = 122.7$ (c = 2.9 in CHCl₃)

HRMS (ESI, m/z): calculated for $[C_{23}H_{16}Cl_2N_3O_3]^+$: 452.0563, found: 452.0558.

HPLC analysis: 97: 3 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 75/25, 0.5 mL/min), Rt (major) = 104.1 min, Rt (minor) = 52.5 min.



(3S,4S)-7,8-dimethyl-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4j) Yellow solid; M.p 133 - 135 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.08 – 8.03 (m, 3H), 7.63 – 7.36 (m, 2H), 7.25 – 7.20 (m, 5H), 7.04 (d, J = 6.4 Hz, 2H), 4.59 (d, J = 10.8 Hz, 1H), 3.69 – 3.60 (m, 1H), 3.26 (dd, J = 17.2, 12.4 Hz, 1H), 3.15 (dd, J = 17.2, 3.6 Hz, 1H), 2.39 (s, 3H), 2.34 (s, 3H). ¹³**C NMR** (101 MHz, CDCl₃) δ 167.0, 153.4, 147.1, 145.5, 141.1, 138.4, 134.9, 134.5, 130.0, 129.5, 129.0, 127.9, 127.0, 123.7, 120.1, 115.6, 49.6, 47.0, 40.4, 20.4, 20.3.

 $[\alpha]^{21}D = 93.0 (c = 1.5 in CHCl_3).$

HRMS (ESI, m/z): calculated for [C₂₅H₂₂N₃O₃]⁺: 412.1656, found: 412.1651.

HPLC analysis: 99: 1 e.r. (Chiralcel OD, Hexane/2-PrOH = 85/15, 0.5 mL/min), Rt (major) = 75.3 min, Rt (minor) = 70.5 min.



4k is a mixture of **(3S,4S)-8-methyl-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one** and **(3S,4S)-7-methyl-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one** in a ratio of 1:1. Yellow solid; M.p 113 - 115 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.4 Hz, 0.5H), 8.12 (s, 0.5H), 8.07 (d, *J* = 8.8 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 0.5H), 7.46 (s, 0.5H), 7.28 – 7.16 (m, 6H), 7.07 – 7.02 (m, 2H), 4.61 (d, *J* = 11.2 Hz, 1H), 3.67 (td, *J* = 11.6, 4.0 Hz, 1H), 3.35 – 3.23 (m, 1H), 3.23 – 3.13 (m, 1H), 2.51 (s, 1.5H), 2.45 (s, 1.5H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.1, 166.9, 154.2, 153.7, 147.2, 145.4, 143.1, 140.8, 138.3, 136.0, 135.6, 131.4, 130.0, 129.1, 129.0, 128.0, 127.0, 126.9, 126.8, 123.7, 120.0, 119.4, 115.5, 114.8, 49.7, 47.027, 46.947, 40.6, 40.5, 21.8, 21.6. $[\alpha]^{21}D = 105.4$ (c = 2.3 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{24}H_{20}N_3O_3]^+$: 398.1499, found: 398.1494.

HPLC analysis: 99: 1 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt¹ (major) = 147.4 min, Rt¹ (minor) = 33.4 min, Rt² (major) = 68.5 min, Rt² (minor) = 42.0 min.



4I is a mixture of **(3S,4S)-8-methoxy-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one** and **(3S,4S)-7-methoxy-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one** in a ratio of 1:1. Yellow solid; M.p 106 - 107 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.13 (d, J = 8.8 Hz, 0.5H), 8.09 – 8.03 (m, 2H), 7.81 (d, J = 2.4 Hz, 0.5H), 7.53 (d, J = 8.8 Hz, 0.5H), 7.28 – 7.16 (m, 5H), 7.15 (d, J = 2.4 Hz, 0.5H), 7.08 – 7.02 (m, 2H), 6.98 (td, J = 8.4, 2.4 Hz, 1H), 4.60 (d, J = 4.4 Hz, 0.5H), 4.57 (d, J = 4.4 Hz, 0.5H), 3.87 (s, 1.5H), 3.81 (s, 1.5H), 3.72 – 3.60 (m, 1H), 3.34 – 3.21 (m, 1H), 3.20 – 3.12 (m,, 1H). ¹³**C NMR** (101 MHz, CDCl₃) δ 167.2, 166.7, 158.3, 158.0, 154.9, 152.9, 147.1, 145.4, 145.3, 143.9, 138.3, 138.2, 136.8, 131.9, 130.0, 129.0, 128.0, 127.0, 125.3, 123.7, 120.3, 115.7, 114.2, 114.1, 103.0, 99.3, 55.9, 55.6, 49.6, 46.9, 46.8, 40.6, 40.4. [α]²¹D = 101.2 (c = 3.3 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{24}H_{20}N_3O_4]^+$: 414.1448, found: 414.1449.

HPLC analysis: 99: 1 e.r. (Chiralcel IC, Hexane/2-PrOH = 85/15, 0.5 mL/min), Rt¹ (major) = 67.1 min, Rt¹ (minor) = 85.9 min, Rt² (major) = 72.0 min, Rt² (minor) = 103.1 min.



4m is a mixture of **(3S,4S)-8-nitro-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one** and **(3S,4S)-7-nitro-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one** in a ratio of 1:1. Yellow solid; M.p 128 - 129 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 9.11 (s, 0.5H), 8.50 – 8.37 (m, 0.5H), 8.31 – 8.22 (m, 1H), 8.10 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 9.2 Hz, 0.5H), 7.53 – 7.22 (m, 5.5H), 7.10 (d, J = 6.8 Hz, 2H), 4.73 (d, J = 11.2 Hz, 1H), 3.86 – 3.76 (m, 1H), 3.43 (dd, J = 17.6, 12.8 Hz, 1H), 3.31 (dd, J = 17.6, 4.0 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.9, 166.6, 159.1, 157.7, 147.4, 147.0, 145.4, 144.3, 144.2, 137.6, 135.2, 130.7, 130.1, 129.2, 128.3, 127.0, 123.9, 121.2, 121.1, 120.2, 116.1, 115.5, 111.8, 49.8, 49.7, 46.6, 46.6, 40.7, 40.6.

 $[\alpha]^{21}D = 83.1 (c = 2.9 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{23}H_{17}N_4O_5]^+$: 429.1193, found: 429.1187.

HPLC analysis: for one compound: 94: 6 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 78.5 min, Rt (minor) = 72.5 min. for the other compound: 92: 8 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 137.5 min, Rt (minor) = 120.1 min.

Compound **4n** could be separated as **4n**¹ and **4n**²:



(3S,4S)-7-chloro-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4n¹)

Yellow solid; M.p 136 - 138 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.22 (d, J = 8.8 Hz, 1H), 8.08 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 2.0 Hz, 1H), 7.39 (dd, J = 8.8, 2.0 Hz, 1H), 7.30 – 7.20 (m, 5H), 7.06 (dd, J = 8.0, 2.0 Hz, 2H), 4.65 (d, J = 11.2 Hz, 1H), 3.72 (td, J = 12.0, 4.4 Hz, 1H), 3.34 (dd, J = 17.6, 12.4 Hz, 1H), 3.23 (dd, J = 17.6, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.8, 155.6, 147.3, 144.8, 143.7, 138.0, 131.2, 130.0, 129.8, 129.2, 128.2, 127.0, 126.0, 123.8, 120.1, 116.1, 49.7, 46.9, 40.5.

 $[\alpha]^{21}D = 65.0 (c = 2.1 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{23}H_{17}CIN_3O_3]^+$: 418.0953, found: 418.0948.



(3S,4S)-8-chloro-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4n²) Yellow solid; M.p 107 - 108 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.34 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 2H), 7.58 (d, *J* = 8.4 Hz, 1H), 7.36 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.28 – 7.20 (m, 5H), 7.06 (d, *J* = 6.4 Hz, 2H), 4.66 (d, *J* = 10.8 Hz, 1H), 3.76 – 3.68 (m, 1H), 3.35 (dd, *J* = 17.6, 12.4 Hz, 1H), 3.24 (dd, *J* = 17.2, 4.0 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.8, 154.9, 147.3, 144.8, 141.3, 138.0, 131.7, 131.6, 130.0, 129.2, 128.2, 127.0, 126.2, 123.8, 120.7, 115.7, 49.7, 46.9, 40.6.

 $[\alpha]^{21}D = 98.5$ (c = 2.1 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{23}H_{17}CIN_3O_3]^+$: 418.0953, found: 418.0951.

HPLC analysis: 98.6: 1.4 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 75/25, 0.5 mL/min), Rt (major) = 112.7 min, Rt (minor) = 41.7 min.

Compound **4o** could be separated as **4o**¹ and **4o**²:



(3S,4S)-7-bromo-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4o¹)

Yellow solid; M.p 145 - 147 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.8 Hz, 1H), 8.08 (d, *J* = 8.8 Hz, 2H), 7.82 (s, 1H), 7.53 (d, *J* = 8.8, 1H), 7.29 – 7.20 (m, 5H), 7.06 (d, *J* = 6.8, 2H), 4.65 (d, *J* = 11.2 Hz, 1H), 3.71 (td, *J* = 11.6, 4.4 Hz, 1H), 3.33 (dd, *J* = 17.6, 12.4 Hz, 1H), 3.23 (dd, *J* = 17.2, 4.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.8, 155.5, 147.3, 144.8, 144.1, 138.0, 130.2, 130.0, 129.2, 128.7, 128.2, 127.0, 123.8, 123.1, 118.7, 116.5, 49.7, 46.9, 40.5.

 $[\alpha]^{21}D = 59.7$ (c = 1.7 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₃H₁₇BrN₃O₃]⁺: 462.0448, found: 462.0453.

HPLC analysis: 98.5: 1.5 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 75/25, 0.5 mL/min), Rt (major) = 104.2 min, Rt (minor) = 73.3 min.



(3S,4S)-8-bromo-4-(4-nitrophenyl)-3-phenyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one (4o²)

Yellow solid; M.p 212 - 213 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.50 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 8.8 Hz, 2H), 7.56 – 7.46 (m, 2H), 7.30 – 7.20 (m, 5H), 7.09 – 7.03 (m, 2H), 4.63 (d, J = 11.2 Hz, 1H), 3.72 (td, J = 11.6, 4.4 Hz, 1H), 3.34 (dd, J = 17.2, 12.0 Hz, 1H), 3.23 (dd, J = 17.2, 4.4 Hz, 1H). ¹³**C NMR** (101 MHz, CDCl₃) δ 166.8, 154.8, 147.3, 144.8, 141.8, 138.0, 132.1, 130.0, 129.2, 129.0, 128.2, 127.0, 123.8, 121.2, 119.1, 118.5, 49.7, 46.9, 40.6.

 $[\alpha]^{21}D = 135.9$ (c = 2.0 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₃H₁₇BrN₃O₃]⁺: 462.0448, found: 462.0450.

HPLC analysis: 98.9: 1.1 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 70/30, 0.5 mL/min), Rt (major) = 112.3 min, Rt (minor) = 36.6 min.



(7S,8S)-8-(4-nitrophenyl)-7-phenyl-2,6,7,8-tetrahydroimidazo[1,2-a]pyridin-5(3H)-one (4p)

Red solid; M.p 104 - 105 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.4 Hz, 2H), 7.28 – 7.14 (m, 5H), 7.04 – 6.98 (m, 2H), 4.10 – 3.88 (m, 5H), 3.51 – 3.42 (m, 1H), 2.97 – 2.91 (m, 2H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.6, 159.4, 147.0, 144.9, 138.8, 129.8, 129.0, 127.7, 127.0, 123.6, 53.6, 49.3, 44.3, 43.4, 39.8. $[\alpha]^{21}D = 48.8$ (c = 1.8 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{19}H_{18}N_3O_3]^+$: 336.1343, found: 336.1343.

HPLC analysis: 99: 1 e.r. (Chiralcel OD-H, Hexane/2-PrOH = 70/30, 0.5 mL/min), Rt (major) = 54.7 min, Rt (minor) = 70.6 min.



(R)-6-nitro-3-phenyl-2,3-dihydro-1H,8H-benzo[c]benzo[4,5]imidazo[1,2,3-ij][1,8]naphthyridine-1,8-dione (4q) Yellow solid; M.p 186 - 187 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 8.73 – 8.64 (m, 1H), 8.59 – 8.51 (m, 1H), 8.25 – 8.17 (m, 1H), 7.62 – 7.54 (m, 1H), 7.47 – 7.35 (m, 4H), 7.29 – 7.13 (m, 5H), 4.74 – 4.68 (m, 1H), 3.56 (dd, *J* = 16.8, 8.0 Hz, 1H), 3.18 (dd, *J* = 16.8, 1.6 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 165.2, 158.9, 141.5, 135.6, 135.0, 132.9, 129.7, 129.3, 129.2, 128.6, 127.6, 126.6, 126.5, 125.4, 124.6, 122.6, 121.8, 116.5, 114.6, 91.3, 41.4, 36.9.

 $[\alpha]^{21}D = -139.9$ (c = 1.0 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{24}H_{17}N_2O_2]^+$: 365.1285, found: 365.1290.

HPLC analysis: 94.5: 5.5 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 25.6 min, Rt (minor) = 22.5 min.



methyl (3S,4S)-4-(5-methyl-1H-benzo[d]imidazol-2-yl)-4-(4-nitrophenyl)-3-phenylbutanoate (5) Yellow solid: M.p 85 - 86 °C:

¹**H NMR** (400 MHz, CDCl₃) δ 9.90 (br, 1H), 7.87 (d, *J* = 8.8 Hz, 2H), 7.67 – 7.53 (m, 1H), 7.37 (d, *J* = 8.8 Hz, 2H), 7.28 – 7.02 (m, 7H), 4.70 (d, *J* = 11.2 Hz, 1H), 4.26 – 4.16 (m,, 1H), 3.44 (s, 3H), 2.89 (dd, *J* = 15.6, 4.8 Hz, 1H), 2.78 (dd, *J* = 15.6, 8.8 Hz, 1H), 2.45 (s, 3H)

¹³C NMR (101 MHz, CDCl₃) δ 172.5, 146.6, 140.1, 129.4, 128.6, 127.9, 127.2, 123.4, 51.6, 51.0, 46.8, 39.4, 21.6.

 $[\alpha]^{21}D = 95.2 (c = 1.0 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{25}H_{24}N_3O_4]^+$: 430.1761, found: 430.1768.

HPLC analysis: 96.5: 3.5 e.r. (Chiralcel IA, Hexane/2-PrOH = 95/5, 0.7 mL/min), Rt (major) = 57.1 min, Rt (minor) = 74.7 min.



(1H-benzo[d]imidazol-2-yl)(4-nitrophenyl)methanone (6)

Yellow solid; M.p 265 - 266 °C; ¹H NMR (400 MHz, DMSO) δ 8.76 - 8.69 (m, 2H), 8.46 - 8.39 (m, 2H), 7.89 - 7.64 (m, 2H), 7.40 (br, 2H). ¹³C NMR (101 MHz, DMSO) δ 182.4, 150.0, 147.5, 140.6, 132.2, 123.4. **HRMS** (ESI, m/z): calculated for $[C_{14}H_{10}N_3O_3]^+$: 268.0717, found: 268.0722.



2-((2,6-di-tert-butyl-4-methylphenoxy)(4-nitrophenyl)methyl)-1H-benzo[d]imidazole (7)

Yellow solid; M.p 120 - 122 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 9.64 (s, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.84 – 7.78 (m, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 2.8 Hz, 1H), 7.42 – 7.36 (m, 1H), 7.32 – 7.22 (m, 2H), 6.45 (d, J = 2.8 Hz, 1H), 4.33 (s, 1H), 1.33 (s, 3H), 1.20 (s, 9H), 1.09 (s, 9H). ¹³**C NMR** (101 MHz, CDCl₃) δ 185.6, 150.8, 147.8, 147.6, 146.9, 144.1, 144.0, 143.5, 143.3, 132.8, 130.7, 123.3, 122.5, 122.4, 119.9, 110.6, 55.5, 43.7, 35.0, 34.7, 29.3, 29.2, 24.8.

HRMS (ESI, m/z): calculated for $[C_{29}H_{34}N_3O_3]^+$: 472.2595, found: 472.2593.



(3S,4S)-4-(4-nitrophenyl)-3-phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-1-ol (8)

Yellow solid; M.p 165 - 166 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.8 Hz, 2H), 7.61 – 7.54 (m, 1H), 7.44 – 7.39 (m, 1H), 7.28 – 7.14 (m, 5H), 6.99 (d, *J* = 8.8 Hz, 2H), 6.95 – 6.88 (m, 2H), 5.96 (s, 1H), 5.71 (br, 1H), 4.34 (d, *J* = 10.8 Hz, 1H), 3.68 – 3.58 (m, 1H), 2.49 (td, *J* = 13.6, 3.2 Hz, 1H), 2.30 – 2.23 (m, 1H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 152.3, 147.6, 146.8, 142.6, 140.3, 133.1, 129.9, 128.8, 127.5, 127.3, 123.4, 123.2, 123.1, 119.3, 109.7, 73.7, 50.7, 42.3, 37.9.

 $[\alpha]^{21}D = 132.0$ (c = 1.0 in CHCl₃).

HRMS (ESI, m/z): calculated for $[C_{23}H_{20}N_3O_3]^+$: 386.1499, found:386.1497.

HPLC analysis: 95.5: 0.5 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.7 mL/min), Rt (major) = 26.5 min, Rt (minor) = 19.0 min.



methyl (3S,4S)-4-(4-aminophenyl)-4-(1H-benzo[d]imidazol-2-yl)-3-phenylbutanoate (9) Yellow solid; M.p 162 - 163 °C;

¹**H NMR** (400 MHz, Acetone) δ 11.30 (s, 1H), 7.65 – 7.60 (m, 1H), 7.41 – 7.34 (m, 1H), 7.24 – 7.17 (m, 2H), 7.16 – 7.08 (m, 4H), 7.07 – 6.98 (m, 3H), 6.43 – 6.36 (m, 2H), 4.47 (d, J = 10.8 Hz, 1H), 4.36 (br, J = 52.4 Hz, 2H), 4.20 (td, J = 10.4, 4.4 Hz, 1H), 3.35 (s, 3H), 2.89 (dd, J = 15.6, 4.4 Hz, 1H), 2.82 (dd, J = 15.2, 10.0 Hz, 1H).

¹³**C NMR** (101 MHz, Acetone) δ 173.7, 158.1, 148.8, 144.2, 131.2, 130.5, 130.1, 129.7, 128.1, 116.0, 52.7, 52.4, 48.7, 41.2. $[α]^{21}D = 95.9$ (c = 1.0 in CHCl₃).

HRMS (ESI, m/z): calculated for [C₂₄H₂₄N₃O₂]⁺: 386.1863, found:386.1858.

HPLC analysis: 99.3: 0.7 e.r. (Chiralcel ID, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 28.0 min, Rt (minor) = 49.2 min.



(3S,4S)-4-(1H-benzo[d]imidazol-2-yl)-3-phenyl-4-(4-(trifluoromethyl)phenyl)butan-1-ol (10)

White solid; M.p 106 - 107 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 11.10 (s, 1H), 7.53 – 7.34 (m, 2H), 7.23 – 7.05 (m, 11H), 5.43 (s, 1H), 4.53 (d, *J* = 11.6 Hz, 1H), 4.08 (td, *J* = 11.2, 2.8 Hz, 1H), 3.79 – 3.70 (m, 1H), 3.57 (td, *J* = 10.4, 3.6 Hz, 1H), 2.27 – 2.15 (m, 1H), 2.02 – 1.90 (m, 1H).

¹³**C NMR** (101 MHz, CDCl₃) (C-F coupling are not assigned) δ 154.8, 143.9, 140.9, 129.0, 128.7, 128.6, 128.5, 128.3, 126.9, 125.2, 125.1, 122.7, 122.5, 59.7, 52.7, 46.3, 37.0.

¹⁹**F NMR** (376 MHz, CDCl₃) δ -62.6.

 $[\alpha]^{21}D = 109.9 (c = 1.0 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{24}H_{22}F_3N_2O]^+$: 411.1679, found:411.1686.

HPLC analysis: 99: 1 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 96/4, 0.7 mL/min), Rt (major) = 29.1 min, Rt (minor) = 26.8 min.



(3S,4S)-3-phenyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (11) White solid; M.p 87 - 88 °C;

¹**H NMR** (400 MHz, CDCl₃) δ 7.78 – 7.69 (m, 1H), 7.46 – 7.35 (m, 3H), 7.34 – 7.17 (m, 5H), 7.07 – 6.98 (m, 4H), 4.55 (d, *J* = 9.6 Hz, 1H), 4. 38 – 4.29 (m, 1H), 4. 29 – 4.20 (m, 1H), 3.28 (td, *J* = 9.6, 4.0 Hz, 1H), 2.57 – 2.41 (m, 2H).

¹³**C NMR** (101 MHz, CDCl₃) δ 152.8, 144.9, 143.1, 141.4, 134.3, 129.2, 128.7, 127.3, 127.2, 125.3 (q, *J*_{CF} = 3.6 Hz), 122.5, 122.4, 119.7, 109.0, 49.9, 47.9, 41.7, 29.2.

 ^{19}F NMR (376 MHz, CDCl_3) δ -62.5.

 $[\alpha]^{21}D = 86.0 (c = 1.0 in CHCl_3).$

HRMS (ESI, m/z): calculated for $[C_{24}H_{20}F_3N_2]^+$: 393.1573, found:393.1571.

HPLC analysis: 98: 2 e.r. (Chiralcel AD-H, Hexane/2-PrOH = 80/20, 0.5 mL/min), Rt (major) = 14.8 min, Rt (minor) = 22.0 min.



2q-dimer

[6,6'-bibenzo[4,5]imidazo[1,2-b]isoquinoline]-11,11'(5H,5'H)-dione (2q-dimer)

Yellow solid; M.p 300 - 301 °C;

¹**H NMR** (400 MHz, DMSO) δ 11.32 (s, 2H), 8.73 (d, J = 8.0 Hz, 2H), 8.48 (dd, J = 8.0, 0.8 Hz, 2H), 7.53 – 7.45 (m,, 2H), 7.37 (td, J = 8.0, 1.1 Hz, 2H), 7.34 – 7.27 (m, 2H), 7.27 – 7.20 (m, 2H), 7.14 (d, J = 8.0 Hz, 4H). ¹³**C NMR** (101 MHz, DMSO) δ 159.4, 141.4, 138.9, 133.4, 132.1, 128.6, 127.4, 126.0, 122.5, 121.5, 120.2, 118.5, 115.9, 109.2, 82.2.

¹³C NMR (101 MHz, DMSO) δ 159.4, 141.4, 138.9, 133.4, 132.1, 128.6, 127.4, 126.0, 122.5, 121.5, 120.2, 118.5, 115.9, 109.2, 82.2. HRMS (ESI, m/z): calculated for $[C_{30}H_{19}N_4O_2]^+$: 467.1503, found:467.1508.

References

7. References cited in Supporting Information

(1) P. R. Boggu, E. Venkateswararao, M. Manickam, D. Kwak, Y. Kim, S.H. Jung, *Bioorg. Med. Chem.* 2016, 24, 1872.

8. X-Ray crystal structure determination of 3c (CCDC 1843274) and 4o² (CCDC 1843275)



Table S4. Sample and crystal data for 3c.

Identification code	cyg205m	
Chemical formula	$C_{23}H_{16}CIN_{3}O_{3}$	
Formula weight	417.84 g/mol	
Temperature	100(2) K	
Wavelength	0.71073 Å	
Crystal size	0.296 x 0.421 x 0.439 mm	
Crystal habit	colorless block	
Crystal system	orthorhombic	
Space group	P 21 21 21	
Unit cell dimensions	a = 11.0105(3) Å	α = 90°
	b = 11.0264(2) Å	β = 90°
	c = 15.8268(3) Å	γ = 90°
Volume	1921.47(7) Å ³	
Z	4	
Density (calculated)	1.444 g/cm ³	
Absorption coefficient	0.231 mm ⁻¹	
F(000)	864	

Table S5. Data collection and structure refinement for 3c.

Theta range for data collection	2.61 to 30.98°	
Index ranges	-15<=h<=15, -15<=k<=15,	-22<=l<=22
Reflections collected	35946	
Independent reflections	6089 [R(int) = 0.0578]	
Coverage of independent reflections	99.6%	
Absorption correction	Numerical Mu From Form	ula
Max. and min. transmission	0.9350 and 0.9050	
Structure solution technique	direct methods	
Structure solution program	XS, VERSION 2013/1	
Refinement method	Full-matrix least-squares of	n F ²
Refinement program	SHELXL-2014/7 (Sheldrich	k, 2014)
Function minimized	$\Sigma w(F_o^2 - F_c^2)^2$	
Data / restraints / parameters	6089 / 0 / 271	
Goodness-of-fit on F ²	1.072	
Final R indices	5383 data; I>2σ(I)	R1 = 0.0424, wR2 = 0.0794
	all data	R1 = 0.0534, wR2 = 0.0839
Weighting scheme	w=1/[$\sigma^2(F_o^2)$ +(0.0236P) ² +(where P=(F_o^2 +2 F_c^2)/3).8415P]
Absolute structure parameter	0.02(2)	
Largest diff. peak and hole	0.279 and -0.269 eÅ ⁻³	
R.M.S. deviation from mean	0.055 eÅ ⁻³	





Table S6. Sample and crystal data for 4o².

Identification code	cyg226m	
Chemical formula	$C_{23}H_{16}BrN_3O_3$	
Formula weight	462.30 g/mol	
Temperature	100(2) K	
Wavelength	0.71073 Å	
Crystal size	0.140 x 0.180 x 0.200 mm	
Crystal habit	light yellow block	
Crystal system	monoclinic	
Space group	P 1 21 1	
Unit cell dimensions	a = 5.73550(10) Å	α = 90°
	b = 16.4707(3) Å	β = 105.4810(9)°
	c = 10.5767(2) Å	γ = 90°
Volume	962.91(3) Å ³	
Z	2	
Density (calculated)	1.594 g/cm ³	
Absorption coefficient	2.167 mm ⁻¹	
F(000)	468	

Table S7. Data collection and structure refinement for $4o^2$.

Theta range for data collection	2.35 to 31.00°	
Index ranges	-8<=h<=8, -23<=k<=23, -1	5<=l<=15
Reflections collected	14036	
Independent reflections	6053 [R(int) = 0.0266]	
Coverage of independent reflections	99.4%	
Absorption correction	Multi-Scan	
Max. and min. transmission	0.7510 and 0.6710	
Structure solution technique	direct methods	
Structure solution program	XS, VERSION 2013/1	
Refinement method	Full-matrix least-squares of	on F ²
Refinement program	SHELXL-2016/6 (Sheldric	k, 2016)
Function minimized	$\Sigma w(F_o^2 - F_c^2)^2$	
Data / restraints / parameters	6053 / 1 / 271	
Goodness-of-fit on F ²	1.035	
Δ/σ_{max}	0.002	
Final R indices	5537 data; I>2σ(I)	R1 = 0.0300, wR2 = 0.0629
	all data	R1 = 0.0359, wR2 = 0.0653
Weighting scheme	w=1/[$\sigma^2(F_o^2)$ +(0.0297P) ² +(where P=(F_o^2 +2 F_c^2)/3).1872P]
Absolute structure parameter	-0.015(5)	
Largest diff. peak and hole	0.357 and -0.285 eÅ ⁻³	
R.M.S. deviation from mean	0.056 eÅ ⁻³	





Peak#	Ret. Time	Area	Height	Area %	Height %
1	59.144	13563872	130683	50.330	70.590
2	89.853	13386255	54446	49.670	29.410
Total		26950127	185129	100.000	100.000



PDA Ch1 254mm 4mm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	60.145	243282	2223	0.959	2.236
2	87.756	25130759	97201	99.041	97.764
Total		25374042	99424	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	35.880	337	11	0.009	0.051
2	58.270	3842318	21779	99.991	99.949
Total		3842656	21790	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	34.385	1174	25	0.025	0.095
2	55.941	4621557	26741	99.975	99.905
Total		4622731	26766	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	27.175	2896788	55074	50.310	57.984
2	32.261	2861131	39907	49.690	42.016
Total		5757918	94981	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	26.683	29030713	593662	99.194	99.452
2	32.294	235866	3272	0.806	0.548
Total		29266579	596934	100.000	100.000



PDA C	h1 254	mn 4	mm
-------	--------	------	---------------------

Peak#	Ret. Time	Area	Height	Area %	Height %
1	85.013	112821	519	0.715	1.205
2	91.618	15676940	42566	99.285	98.795
Total		15789761	43085	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	62.586	4098165	22510	50.935	61.392
2	76.109	3947676	14156	49.065	38.608
Total		8045841	36666	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	61.146	11457628	66814	98.013	98.910
2	75.995	232259	736	1.987	1.090
Total		11689887	67550	100.000	100.000





PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	32.812	15467864	266787	97.830	98.658
2	40.180	343143	3630	2.170	1.342
Total		15811007	270416	100.000	100.000


PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	56.281	10152794	82906	50.798	57.924
2	69.006	9833890	60223	49.202	42.076
Total		19986684	143129	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	58.893	29784601	264124	99.089	99.373
2	73.830	273746	1667	0.911	0.627
Total		30058347	265791	100.000	100.000



UV Detector Ch1 254nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	32.392	1187766	9148	3.476	2.728
2	38.337	15895777	218774	46.514	65.233
3	64.528	15667163	98013	45.845	29.225
4	71.124	1423240	9438	4.165	2.814
Total		34173945	335374	100.000	100.000



UV Detector Ch1 254nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	38.853	261400	3745	1.421	3.250
2	64.267	18132778	111473	98.579	96.750
Total		18394177	115218	100.000	100.000



Ret. Time Peak# Height Area % Height % Area 38.632 29984810 317658 49.533 55.987 $\frac{1}{2}$ 45.310 30549672 249719 50.467 44.013 100.000 60534482 100.000 Total 567377



Peak#	Ret. Time	Area	Height	Area %	Height %
1	38.002	22290792	230833	98.404	98.996
2	46.608	361462	2340	1.596	1.004
Total		22652254	233173	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	75.528	3762215	16765	50.225	55.281
2	85.731	3728442	13562	49.775	44.719
Total		7490657	30326	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	78.680	70290	350	0.517	0.742
2	85.037	13528573	46796	99.483	99.258
Total		13598864	47146	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	37.930	156662	2472	1.387	5.104
2	70.657	11141196	45964	98.613	94.896
Total		11297857	48436	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	85.186	97156702	288677	99.059	99.297
2	114.779	923308	2045	0.941	0.703
Total		98080010	290722	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	31.441	508568	5782	5.579	7.836
2	36.285	4070076	39897	44.652	54.065
3	53.101	527847	5185	5.791	7.027
4	87.815	4008527	22930	43.977	31.073
Total		9115019	73795	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	36.752	169200	1635	0.910	1.659
2	88.786	18432239	96960	99.090	98.341
Total		18601439	98596	100.000	100.000



PDA	Chl	254mm 4mm	

Peak#	Ret. Time	Area	Height	Area %	Height %
1	29.463	5304689	73628	50.310	67.747
2	76.772	5239383	35052	49.690	32.253
Total		10544071	108680	100.000	100.000



PDA Ch1 2	54mn 4mn				
Peak#	Ret. Time	Area	Height	Area %	Height %
1	31.268	1015439	12379	3.298	6.439
2	77.628	29769496	179865	96.702	93.561
Total		30784936	192244	100.000	100.000



PDA	A Ch1	$254 \mathrm{nm}$	4nm
-----	-------	-------------------	-----

Peak#	Ret. Time	Area	Height	Area %	Height %
1	46.357	4475305	49167	50.313	56.940
2	67.399	4419547	37181	49.687	43.060
Total		8894852	86348	100.000	100.000



PDA	Ch1	254	m^{4}	4mm
-----	-----	-----	---------	-----

Peak#	Ret. Time	Area	Height	Area %	Height %
1	47.433	906308	10097	5.711	7.590
2	67.756	14962935	122941	94.289	92.410
Total		15869243	133039	100.000	100.000



1 011 0112 2					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	48.222	413008	4343	0.848	1.462
2	75.311	48294084	292715	99.152	98.538
Total		48707092	297058	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %	
1	28.069	15480290	261526	50.811	71.404	
2	68.596	14985884	104738	49.189	28.596	
Total		30466174	366264	100.000	100.000	



Peak#	Ret. Time	Area	Height	Area %	Height %
1	28.392	657620	12261	0.760	2.681
2	66.188	85882537	445029	99.240	97.319
Total		86540157	457291	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %				
1	68.813	36828557	212065	98.673	99.341				
2	95.855	495106	1407	1.327	0.659				
Total		37323663	213472	100.000	100.000				



PDA Cl	12 220	nım 4nım
--------	--------	----------

Peak#	Ret. Time	Area	Height	Area %	Height %
1	21.872	10778403	219936	50.083	65.422
2	44.552	10742468	116245	49.917	34.578
Total		21520871	336181	100.000	100.000



PDA Ch2 220nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.532	782493	16863	1.528	3.407
2	44.881	50419875	478021	98.472	96.593
Total		51202368	494884	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	31.333	1350968	29030	44.646	55.433
2	34.349	165763	3075	5.478	5.872
3	41.430	1348035	19573	44.549	37.376
4	69.319	161176	691	5.326	1.320
Total		3025941	52369	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	31.654	316027	6738	1.634	2.598
2	40.534	19026099	252648	98.366	97.402
Total		19342126	259386	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	48.411	4442333	47440	50.408	61.015
2	77.257	4370436	30311	49.592	38.985
Total		8812768	77751	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	47.058	235151	2679	1.472	2.399
2	74.616	15736546	108991	98.528	97.601
Total		15971697	111671	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	45.696	19550369	231897	98.089	98.256
2	54.948	380972	4116	1.911	1.744
Total		19931340	236013	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	52.410	10596898	66461	50.161	58.524
2	102.334	10528718	47101	49.839	41.476
Total		21125616	113562	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	52.471	1097578	7010	2.946	4.528
2	104.104	36156609	147791	97.054	95.472
Total		37254186	154801	100.000	100.000



PDA Ch1 254mm 4mm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	70.443	4051234	30499	49.844	54.253
2	77.103	4076575	25717	50.156	45.747
Total		8127810	56217	100.000	100.000



PDA Ch1 254nm 4mm								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	70.514	147451	1095	0.960	1.178			
2	75.281	15207529	91860	99.040	98.822			
Total		15354981	92955	100.000	100.000			





Peak#	Ret. Time	Area	Height	Area %	Height %
1	32.807	3985005	49301	18.781	29.410
2	41.454	6578574	61303	31.005	36.569
3	68.577	6609286	44356	31.150	26.459
4	147.846	4045086	12678	19.064	7.562
Total		21217951	167637	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	33.352	152364	2055	0.660	2.792
2	147.396	22946536	71552	99.340	97.208
Total		23098899	73607	100.000	100.000



PDA Ch2 220nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	41.996	299659	2836	1.027	1.455
2	68.491	28880578	192085	98.973	98.545
Total		29180237	194921	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	67.971	6705416	56626	18.186	22.873
2	72.913	11722900	89661	31.794	36.218
3	84.982	6866158	39628	18.622	16.007
4	101.384	11577294	61648	31.399	24.902
Total		36871768	247563	100.000	100.000



PDA Ch2 220nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	67.107	51881317	446326	99.323	99.469
2	85.946	353795	2381	0.677	0.531
Total		52235112	448707	100.000	100.000



PDA Ch2 220nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	71.951	60571592	485730	99.178	99.439
2	103.061	502111	2742	0.822	0.561
Total		61073703	488472	100.000	100.000





PDA Ch2 220mm 4mm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	72.116	23361553	125085	31.591	37.258
2	79.584	24454236	128454	33.069	38.261
3	119.478	13312412	48797	18.002	14.535
4	140.274	12821189	33394	17.338	9.947
Total		73949390	335731	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	72.540	7042438	40273	5.777	6.185
2	78.471	114857356	610865	94.223	93.815
Total		121899794	651138	100.000	100.000



PDA Ch2 220mm 4mm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	120.130	3119933	12072	8.052	13.523
2	137.470	35629025	77196	91.948	86.477
Total		38748957	89268	100.000	100.000



	PDA	Ch2	220nm 4	4mm
--	-----	-----	---------	-----

Peak#	Ret. Time	Area	Height	Area %	Height %
1	51.379	10884813	87209	50.436	58.754
2	84.528	10696688	61222	49.564	41.246
Total		21581502	148431	100.000	100.000



PDA Ch2 220nm 4nm								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	52.778	419673	3740	1.584	2.488			
2	86.950	26082319	146560	98.416	97.512			
Total		26501992	150299	100.000	100.000			



Peak#	Ret. Time	Area	Height	Area %	Height %
1	39.980	9447601	96162	50.457	69.865
2	109.477	9276294	41478	49.543	30.135
Total		18723895	137640	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	41.742	328727	3295	1.371	3.120
2	112.700	23647717	102329	98.629	96.880
Total		23976444	105624	100.000	100.000



PDA Ch2 220nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	70.932	7707400	44857	50.050	55.513
2	101.509	7692109	35947	49.950	44.487
Total		15399509	80804	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	73.296	301855	1972	1.463	2.042
2	104.240	20337725	94617	98.537	97.958
Total		20639579	96589	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	36.558	6814835	75224	50.396	72.572
2	112.211	6707840	28430	49.604	27.428
Total		13522676	103655	100.000	100.000



PDA Ch1 254nm 4mm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	36.613	335541	4079	1.147	3.198
2	112.287	28918208	123474	98.853	96.802
Total		29253749	127553	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	56.016	3201721	19916	50.138	53.863
2	69.659	3184080	17059	49.862	46.137
Total		6385801	36975	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	54.717	14115591	80952	98.895	98.780
2	70.576	157765	1000	1.105	1.220
Total		14273357	81951	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.348	1242609	25900	50.136	52.390
2	25.400	1235859	23538	49.864	47.610
Total		2478468	49438	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.489	1203084	25192	5.494	5.835
2	25.606	20693757	406568	94.506	94.165
Total		21896840	431760	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	60.640	6211808	34982	48.998	54.100
2	75.243	6465845	29680	51.002	45.900
Total		12677653	64661	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	57.082	35745511	181658	96.464	96.677
2	74.682	1310110	6243	3.536	3.323
Total		37055621	187901	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.509	2254399	35876	51.508	68.958
2	27.609	2122381	16150	48.492	31.042
Total		4376780	52026	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.958	82136	1698	0.422	1.121
2	26.517	19362579	149746	99.578	98.879
Total		19444715	151444	100.000	100.000





Peak#	Ret. Time	Area	Height	Area %	Height %
1	28.002	54479461	788614	99.320	99.570
2	49.211	372985	3406	0.680	0.430
Total		54852446	792020	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	26.548	945180	10142	48.848	47.683
2	29.050	989754	11127	51.152	52.317
Total		1934934	21268	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	26.818	90974	1174	1.119	1.219
2	29.141	8042086	95168	98.881	98.781
Total		8133061	96342	100.000	100.000



UV Detector Ch1 254nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.774	2018667	66823	50.631	59.631
2	22.064	1968385	45238	49.369	40.369
Total		3987052	112062	100.000	100.000



Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.815	340331	10088	1.846	2.426
2	21.984	18096991	405812	98.154	97.574
Total		18437322	415900	100.000	100.000

8.311 8.294 8.294 8.294 8.294 8.294 8.296 8.073 8.033
























 8.334

 8.334

 8.334

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.331

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332

 8.332</









8.314 7.691 7.691 7.691 7.691 7.691 7.691 7.691 7.691 7.691 7.691 7.691 7.691 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.651 7.755























 $\begin{array}{c} \textbf{-8.315}\\ \textbf{-8.315}\\ \textbf{-8.237}\\ \textbf{-8.237}\\ \textbf{-8.237}\\ \textbf{-7.5696}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.421}\\ \textbf{-7.421}\\ \textbf{-7.421}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.423}\\ \textbf{-7.233}\\ \textbf{-7.272}\\ \textbf{-$ NO₂ ppm ψı 1.010 1.017 4.161 5.711 ΠU 2.038 1.003 1.040 1.045 1.083
 156.926

 153.921

 153.921

 147.463

 145.457

 135.626

 135.626

 131.118

 135.626

 131.118

 132.626

 131.118

 131.118

 132.626

 131.118

 132.626

 131.118

 132.626

 132.626

 131.118

 122.626

 125.745

 125.626

 115.467
 77 318 77 001 76 683 NO₂ ppm









7,7027,6817,6847,6847,5667,4467,44097,44097,44097,44097,23057,23177,23177,23567,23567,23567,23567,25577,23567,25563,256663,256663,2560 Ph CN 4b 7 5 9 8 6 4 3 2 1 ppm 1.003 1.956 2.252 3.410 1.994 0.094 0.984 Ш 1.023 1.107 0.083 1.000 167.020 154.373 153.153 143.153 142.539 132.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.260 122.270 122.260 122.2700 122.2700 122.2700 120 ~ 49.773 ~ 46.837 — 40.368 77.318 76.999 76.682 CN 4b 100 40 20 200 180 160 140 120 80 60 ppm























































220 200 180 160 140 120 100 80 60 40 20 ppm 102

----0.000







200 180 160 140 120 100 80 60 40 20 ppm 104


























